In ITT patients, PD-1/PD-L1 inhibitors often increase the incidence of irAEs, a phenomenon partly attributed to the potential cross-reactivity between tumor neoantigens and normal tissue antigens, which can trigger abnormal activation of the immune system (36). Here, CD274 is linked to neoplasm.